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ABSTRACT 
Aims: Peritoneal protein loss due to high peritoneal permeability may contribute to 
hypoalbuminemia and early withdrawal from peritoneal dialysis (PD) therapy in end 
stage renal disease (ESRD) patients. We have found that pigment epithelium-derived 
factor (PEDF) has anti-vasopermeability properties both in cell culture and animal 
models by counteracting the biological actions of vascular endothelial growth factor 
(VEGF). However, it remains unknown which clinical variables, including dialysate 
VEGF and PEDF, were associated with decreased serum albumin levels and could 
predict early withdrawal from the PD in ESRD patients. We addressed the issues.  
Methods: Twenty-seven ESRD patients undergoing PD were enrolled. Clinical variables 
were measured at 6 months after commencing PD. We examined the independent 
correlates of serum albumin in PD patients and then prospectively investigated the 
predictors of withdrawal from the PD therapy during 4 years.  
Results: Dialysate VEGF was associated with peritoneal solute transport rate (p=0.002), 
serum albumin (inversely, p<0.001) and dialysate PEDF levels (p<0.001). In multiple 
stepwise regression analysis, age (p=0.002) and dialysate VEGF levels (p<0.001) were 
independent determinants of serum albumin levels. High VEGF (>27 pg/ml), low serum 
albumin (≤3.31 g/dl) and low hemoglobin (≤11.2 g/dl) were correlated with withdrawal 
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from the PD therapy during the 4 years. The odds ratio of dialysate VEGF for early 
withdrawal from the PD was 6.310 (p=0.035).  
Conclusion: The present study demonstrated that increased dialysate VEGF was 
associated with decreased serum albumin and early withdrawal from the PD therapy. 
Inhibition of peritoneal VEGF production may be a therapeutic target in PD patients. 
 
KEY WORDS; hypoalbuminemia, peritoneal dialysis, PEDF, VEGF, withdrawal 
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INTRODUCTION 
 Hypoalbuminemia is associated with increased risks of all-cause, 
cardiovascular and infection-related mortality in end stage renal disease (ESRD) 
patients undergoing peritoneal dialysis (PD) (1-4). It is generally considered that 
malnutrition, inflammatory reactions, impaired immune systems, and hypoalbuminemia 
are interrelated with each other, which could in concert cause ultrafiltration failure of 
the peritoneum, thereby being involved in early withdrawal from the PD therapy (5-7). 
Furthermore, prognosis of ESRD patients remaining on PD treatment was reported to be 
better than those who withdrew from the therapy (8). Therefore, to clarify the 
biomarkers that could be linked to hypoalbuminemia and may predict early withdrawal 
from the PD is not only helpful for identifying high-risk ESRD patients on PD, but also 
may be useful for developing a novel therapeutic strategy that could improve the 
prognosis in these subjects.  
Peritoneal protein loss due to high peritoneal permeability may contribute to 
hypoalbuminemia in ESRD patients with PD therapy (9). Indeed, in a cross-sectional 
study of 106 continuous ambulatory PD (CAPD) patients, 4-hour dialysate to plasma 
creatinine ratio (D/P Cr) was shown to be an independent risk factor for decreased 
serum albumin levels in these patients (10). Vascular endothelial growth factor (VEGF) 
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is one of the potent angiogenic mitogens specific for endothelial cells, also known as 
vascular permeability factor (11). VEGF is produced by human peritoneal tissues, and 
its expression in the peritoneum was significantly increased in PD patients compared 
with normal subjects (12). Moreover, increased dialysate VEGF levels were correlated 
with high peritoneal solute transport rate in ESRD patients (11). On the other hand, we, 
along with others, have recently found that pigment epithelium-derived factor (PEDF), a 
glycoprotein that belongs to the superfamily of serine protease inhibitors, has 
anti-angiogenic and anti-vasopermeability properties both in cell culture and animal 
models by counteracting the biological actions of VEGF (13). Therefore, a balance 
between VEGF and PEDF in the peritoneum may regulate the peritoneal permeability 
and protein loss in PD patients. However, it remains unknown which clinical variables, 
including dialysate VEGF and PEDF, were associated with decreased serum albumin 
levels and could predict early withdrawal from the PD in ESRD patients. In this study, 
we examined the independent correlates of serum albumin levels in PD patients and 
then prospectively investigated the predictors of withdrawal from the PD therapy during 
4 years. 
 
METHODS 
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Patients 
 Twenty-seven ESRD patients (16 male and 11 female; mean age 53.1 ± 17.3 
years old; diabetic nephropathy (n=3), chronic glomerulonephritis (n=9), hypertensive 
nephrosclerosis (n=2), amyloidosis (n=1), Fabry disease (n=1), hypoplastic kidney 
(n=2) and etiology unknown (n=9)) who were initiated PD therapy from 2005 to 2008 
years were enrolled in the present study. The patients with a previous history of 
peritonitis were excluded. All patients initially received PD therapy with commercially 
available glucose- and icodextrin-based dialysis solutions. Six months after 
commencing the PD, clinical variables were measured. Twenty-five patients received 
inhibitors of renin-angiotensin system (RAS) for the treatment of hypertension and 5 
patients received statins for dyslipidemia. We complied the withdrawal criteria from the 
“Study Group for Withdrawal from PD in Japan” (14). 
  
Data collection  
 Body mass index (kilograms per meter squared) was calculated as an index of 
the presence or absence of obesity. Blood was drawn for determinations of hemoglobin 
(Hb), total protein (TP), serum albumin, lipids (total-cholesterol and triglycerides), 
blood urea nitrogen (BUN), creatinine and uric acid. Serum high-sensitive C-reactive 
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protein (hsCRP) was measured with nepherometry (N-Latex, CRPII, Dade Behring Co., 
Tokyo, Japan) (15). VEGF (R&D systems, Minneapolis, MN, USA) and PEDF levels in 
the dialysate effluent were measured by an enzyme-linked immunosorbent assay system 
as described previously (16). Other chemistries were measured at a commercially 
available laboratory (Wako Pure Chemical Industries, Ltd, Osaka, Japan) (15). The 
standard peritoneal equilibration test (PET) was evaluated as dialysate to plasma 
creatinine ratio (D/P Cr). Weekly Kt/V and residual renal function were evaluated by 
PD adequest 2.0 software (Baxter Healthcare, Deerfield, IL, U.S.A.) (17). Informed 
consent was obtained from all patients, and studies were approved by ethics committees 
of the Kurume University School of Medicine, Japan. 
 
Statistical analysis 
 Data are presented as mean ± standard deviation (SD). Sex, medications for 
hypertension and dyslipidemia (RAS inhibitors and statin), the presence or absence of 
diabetes mellitus, and withdrawal or non-withdrawal patients were coded as dummy 
variables. Clinical data that were not normally distributed such as triglyceride, hsCRP 
and intact parathyroid hormone (PTH) were log-transformed. To determine the 
independent correlates of serum albumin levels, univariate and multiple stepwise 
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regression analyses were performed. To explore the characteristics factors for predicting 
the withdrawal from PD, univariate liner regression analysis was performed. Further, 
dialysate VEGF, serum albumin and Hb levels were divided into two groups according 
to the cut-off point by calculating the sensitivity and specificity in receiver operating 
characteristic (ROC) analysis. Then cumulative retention rate of PD therapy during the 
4 years was tested by the Kaplan-Meier method and interpreted using the log-rank 
statistical analysis. Cox regression analysis was also performed to estimate the odds 
ratio for withdrawal of PD. Statistical significance was defined as p<0.05. All statistical 
analyses were performed with SPSS system (Ver. 20, SPSS, Chicago, IL, USA). 
 
RESULTS 
Demographic data 
 Demographic baseline data are shown in Table 1. VEGF and PEDF levels in 
the effluent dialysate were 34.1 ± 17.5 pg/ml and 1.88 ± 2.18 g/ml, respectively. 
Serum albumin (3.35 ± 0.67 g/dl) and Hb (10.6 ± 0.9 g/dl) levels were lower, while 
hsCRP levels (863 (124-6010) ng/ml) were higher than the normal ranges. Mean D/P Cr 
in our subjects was 0.61 ± 0.15.  
 
Hazama et al.  
9 
Correlates of serum albumin levels 
 Univariate analysis showed that age (inversely, p=0.012), dialysate VEGF 
(inversely, p<0.001) and PEDF (inversely, p=0.040) levels were correlated with serum 
albumin levels (Table 2). Because these parameters could be closely correlated with 
each other, to determine the independent determinants of serum albumin, multiple 
stepwise regression analysis was performed. This analysis showed that age (=-.427, 
p=0.002) and dialysate VEGF (=-.659, p<0.001) were independently correlated with 
serum albumin levels (Table 2).  
 
Correlates of dialysate VEGF  
 We next examined the independent determinants of dialysate VEGF. As shown 
in Fig. 1 and 2, dialysate VEGF was correlated with D/P Cr (p=0.002, r=0.569), serum 
albumin (inversely, p<0.001, r=0.697) and dialysate PEDF levels (p<0.001, r=0.647). 
These variables were independent determinants of dialysate VEGF in our patients (data 
not shown).  
 
Correlates of withdrawal from the PD 
 We then investigated prospectively whether dialysate VEGF was correlated 
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with withdrawal from the PD during 4 years. During 4 years, 7 patients (26%) received 
antibiotics therapy due to infectious peritonitis. Eleven patients remained on PD 
treatment, whereas 16 patients withdrew from the therapy due to the following reasons 
(peritonitis (n=4), ultrafiltration failure (n=9), death (n=2), and renal transplantation 
(n=1)). 
Univariate analysis revealed that dialysate VEGF (p=0.039), serum albumin 
(inversely, p=0.039) and Hb (inversely, p=0.034) levels were significantly correlated 
with withdrawal from the PD therapy (Table 3). When dialysate VEGF, serum albumin 
and Hb levels were divided into two groups according to the ROC analysis (cut-off 
points of VEGF, serum albumin and Hb were 27 pg/ml, 3.31g/dl and 11.2 g/dl, 
respectively), levels of VEGF >27 pg/ml, serum albumin ≤3.31 g/dl and Hb ≤11.2 g/dl 
were associated with lower cumulative retention rate of the PD therapy during 4 years 
(Fig. 3). As shown in Table 4, the odds ratio (OR) of dialysate VEGF for early 
withdrawal from the PD (7.864, 95% CI 1.707-36.220) was statistically significant 
(p=0.013), while that of serum albumin or Hb not (OR 2.957, 95% CI 0.984-8.885, 
p=0.053, 4.235, 95% CI 0.950-18.885, p=0.058, respectively). Multivariate analysis 
revealed that dialysate VEGF was independently correlated with withdrawal from the 
PD during 4 years (OR 6.310, 95% CI 1.137-35.021, p=0.035). 
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DISCUSSION 
 We demonstrated in this study that; [1] dialysate VEGF was an independent 
determinant of serum albumin levels in PD patients; [2] high VEGF (VEGF >27 pg/ml), 
low serum albumin (serum albumin ≤3.31 g/dl) and low Hb (Hb ≤11.2 g/dl) levels were 
correlated with low cumulative retention rate of PD therapy during the 4 years; and [3] 
dialysate VEGF was independently correlated with early withdrawal from the PD 
therapy in ESRD patients. 
 In this study, VEGF levels in the effluent dialysate were positively associated 
with peritoneal solute transport rate and inversely correlated with serum albumin levels. 
Given the vasopermeable properties of VEGF, our present results suggest that VEGF 
may induce peritoneal hyperpermeability and subsequently evoke albumin leakage into 
the peritoneal cavity, thereby causing hypoalbuminemia in our patients. Peritoneal 
albumin excretion has been shown to strongly predict future cardiovascular events in 
PD patients (7). Since VEGF levels in the peritoneum were increased in PD patients 
(12) and that inhibition of VEGF ameliorated the peritoneal permeability in diabetic rats 
(18), peritoneal production of VEGF and/or its biological actions may be a novel 
therapeutic target for hypoalbuminemia and increased cardiovascular events in PD 
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patients. Further, in our prospective study, dialysate VEGF was a sole independent 
determinant for early withdrawal from the PD. So, VEGF levels >27 pg/ml in the 
effluent dialysate may be a marker that could predict early withdrawal from  PD 
therapy and future cardiovascular events in PD patients.  
 In our study, basal dialysate VEGF levels were not associated with 
peritonitis-induced withdrawal from the PD (r=0.046, p=0.891) or future peritonitis 
(r=0.086, p=0.670). However, the levels could predict future ultrafiltration failure in 
these subjects (r=0.434, p=0.024). These observations suggest that dialysate VEGF 
could not only affect membrane hyperpermeability, but also impair peritoneal 
membrane function in PD patients.  
In this study, we cannot exactly identify the source of VEGF in the effluent 
dialysate of our patients. However, dialysate VEGF levels were not correlated with 
serum levels of VEGF (data not shown). Moreover, total protein levels in the dialysate 
effluent were not also correlated with dialysate VEGF (data not shown). Therefore, it is 
unlikely that dialysate VEGF was released passively from the circulating blood.  
 PEDF has been shown to block the VEGF-induced retinal vascular 
permeability in rats (19) and ameliorate retinal and renal vascular hyperpermeability in 
animal models of diabetic retinopathy and nephrotic syndrome, by reducing the VEGF 
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expression, respectively (20, 21). In this study, we demonstrated that PEDF levels in the 
dialysate effluent were positively associated with VEGF levels, and dialysate PEDF was 
one of the independent determinants of VEGF in the effluent dialysate. Since the 
significant inverse correlation between dialysate PEDF and serum albumin levels was 
lost after the adjustment for dialysate VEGF, dialysate PEDF levels may be increased in 
response to VEGF for counteracting its biological actions in the peritoneum. Therefore, 
administration of high-dose of PEDF into the peritoneal cavity and/or pharmacological 
up-regulation of PEDF production in the peritoneum could be a therapeutic strategy for 
hypoalbuminemia and early withdrawal from the PD therapy in ESRD patients. 
 Dialysate VEGF values (34.1 ± 17.5 pg/ml) in our patients were lower than 
those of previous reports; mean dialysate VEGF levels in low and high permeability 
groups evaluated by PET were 60.3 (19-159; range) and 96.3 (34.3-540; range) pg/ml, 
respectively in one report (11), whereas VEGF levels were 58.6 ± 33.7 pg/ml in the 
other (22). We did not know the exact reasons for the discrepant results between ours 
and theirs. Although RAS inhibition could alter dialysate VEGF levels, there was no 
association of the VEGF levels with the use of RAS inhibitors in our subjects (r=0.217, 
p=0.277). So, it is unlikely that the presence or absence of RAS inhibitors could affect 
the present findings. The difference in PD duration, concentration of glucose in the PD 
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solution and/or number of diabetic patients could account for the discrepancy.  
 
LIMITATIONS 
 We found that dialysate VEGF levels were an independent risk factor for early 
withdrawal from PD. However, it might not be clinically practical to measure the 
dialysate VEGF value in PD patients. Therefore, studies to identify more convenient 
factors that could determine the dialysate VEGF levels in the clinical setting are needed.  
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FIGURE LEGENDS 
 
Fig 1. (A) Correlation between dialysate VEGF and D/P Cr levels in patients with PD. 
(B) Correlation between dialysate VEGF and serum albumin levels in patients with PD.  
VEGF; vascular endothelial growth factor, D/P Cr; dialysate to plasma creatinine ratio. 
 
Fig 2. Correlation between dialysate VEGF and PEDF levels in patients with PD.  
VEGF; vascular endothelial growth factor, PEDF; pigment epithelium-derived factor. 
 
Fig 3. Cumulative retention rate of PD patients. 
VEGF; vascular endothelial growth factor, Hb; hemoglobin. 
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TABLE 1. Clinical characteristics of patients 
 
No of patients    27 
Age (years old)             53.1 ± 17.3 
Sex (male/female)          16/11 
BMI (kg/m2)          21.0 ± 3.1 
Hb (g/dl)           10.6 ± 0.9 
TP (g/dl)     6.34 ± 0.81 
Serum albumin (g/dl)   3.35 ± 0.67 
Total cholesterol (mg/dl)              183 ± 54 
Triglyceride* (mg/dl) (range)  132 (53-493) 
BUN (mg/dl)               54.3 ± 11.2 
Serum creatinine (mg/dl)          9.60 ± 2.88 
Uric acid (mg/dl)    6.91 ± 1.36 
HsCRP* (ng/ml) (range)   863 (124-6010) 
Intact PTH* (mg/dl) (range)   172 (23-500) 
D/P Cr                0.61 ± 0.15 
Dialysate VEGF (pg/ml)             34.1 ± 17.5 
Dialysate PEDF (g/ml)   1.88 ± 2.18  
Dialysate TP (mg/dl)   18.2 ± 12.8 
Residual renal function (l/week/1.73m2) 0.60 ± 0.42 
KT/V          1.85 ± 0.49 
Diabetes mellitus (-/+) (%)   24/3 (11) 
 Medication 
  RAS inhibitors (-/+) (%)   2/25 (93) 
  Statins  (-/+) (%)   22/5 (19) 
 
Values are shown as mean ± SD or median (range). *Log-transformed values were used. No= 
number; BMI=body mass index; Hb=hemoglobin; TP=total protein; BUN=blood urea nitrogen; 
HsCRP=high-sensitive C-reactive protein; PTH=parathyroid hormone; D/P Cr=dialysate to 
plasma creatinine ratio, VEGF=vascular endothelial growth factor; PEDF=pigment 
epithelium-derived factor; RAS=renin angiotensin system.  
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TABLE 2. Univariate and multiple stepwise regression analysis for the correlates of serum 
albumin levels 
          Univariate analysis  Multiple stepwise analysis 
 
Variables    SE P-value    SE P-value 
 
Age   -.485 .007 0.012  -.427 .005 0.002 
Sex   -.053 .272 0.797 
BMI   -.118 .049 0.582 
Hb   -.283 .146 0.161 
BUN   -.026 .012 0.901 
Serum creatinine  .029 .048 0.886 
Uric acid   -.119 .101 0.563 
Total cholesterol  .240 .003 0.249 
Triglyceride*  .149 .237 0.498 
HsCRP*   -.148 .116 0.471 
Intact PTH*  .114 .157 0.587 
D/PCr   -.360 .919 0.077 
Dialysate VEGF  -.697 .006 <0.001  -.659 .005 <0.001 
Dialysate PEDF  -.406 .057 0.040 
Dialysate TP  .121 .010 0.631 
Residual renal function .010 .470 0.968 
KT/V   .478 .411 0.052 
Diabetes mellitus  -.739 -.358 0.073 
Use of RAS inhibitors  .145 .058 0.777 
Use of statins  .523 .313 0.120 
 
*Log-transformed values are used. , standardized regression coefficients. SE, standard error. 
R2=0.666, BMI=body mass index; Hb=hemoglobin; BUN=blood urea nitrogen; 
HsCRP=high-sensitive C-reactive protein; PTH=parathyroid hormone; D/P Cr=dialysate to 
plasma creatinine ratio, VEGF=vascular endothelial growth factor; PEDF=pigment 
epithelium-derived factor; RAS=renin angiotensin system.  
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TABLE 3. Univariate regression analysis for the correlates of withdrawal of PD 
    
  Variables    SE P-value 
  Age   -.171 .006 0.404   
  Sex   -.123 .206 0.549 
  BMI   -.268 .034 0.260 
  Hb   -.416 .105 0.034 
  Serum albumin  -.416 .141 0.039 
  BUN   .262 .009 0.197 
  Creatinine  -.019 .035 0.928 
  Uric acid   .250 .076 0.228 
  Total cholesterol  -.153 .002 0.474 
  Triglyceride*  -.190 .171 0.386 
  HsCRP*   .304 .083 0.130 
  D/PCr   .161 .708 0.422 
  Dialysate VEGF  .407 .005 0.039   
  Dialysate PEDF  .289 .046 0.152 
  Dialysate TP  .313 .315 0.750 
  Residual renal function .115 .274 0.660 
  Weekly KT/V  -.143 .240 0.585 
  Diabetes mellitus  .066 .378 0.750 
  Use of RAS inhibitors .045 .378 0.827 
  Use of statins   -.175 .252 0.393 
 
*Log-transformed values are used. , standardized regression coefficients. SE, standard error. 
PD=peritoneal dialysis; BMI=body mass index; Hb=hemoglobin; BUN=blood urea nitrogen; 
HsCRP=high-sensitive C-reactive protein; D/P Cr=dialysate to plasma creatinine ratio, 
VEGF=vascular endothelial growth factor; PEDF=pigment epithelium-derived factor; TP=total 
protein; RAS=renin angiotensin system.  
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TABLE 4. OR for the withdrawal of PD during the 4 years 
 
 Crude model   Bivariate model1          Multivariate model2 
 OR (95% CI)         P   OR (95% CI)          P  OR (95% CI)         P 
VEGF*  7.864(1.707-36.220)  0.013 7.439(1.332-41.383)  0.022 6.310(1.137-35.021)  0.035 
Albumin* 2.957(0.984-8.885)   0.053 1.092(0.317-3.754)   0.889  
Hb* 4.235(0.950-18.885)  0.058   
 
*Values were categorized into two groups according to the cut-off value. 1Bivariate model 
includes VEGF and albumin simultaneously. 2Multiple model includes VEGF, albumin and 
hemoglobin. OR=odds ratio; PD=peritoneal dialysis; VEGF=vascular endothelial growth factor; 
Hb=hemoglobin. 
 
 
FIG. 1. 
 (A) Correlation betweendialysate VEGF and D/P Cr levels in patients undergoing 
peritoneal dialysis (PD). (B) Correlation between dialysate VEGF and serum albumin 
levels in patients with PD. VEGF, vascular endothelial growth factor; D/P Cr, dialysate 
to plasma  
creatinine ratio. 
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FIG. 2. 
Correlation between dialysate VEGF and PEDF levels in patients undergoing 
peritoneal dialysis (PD). VEGF, vascular endothelial growth factor; PEDF, pigment 
epithelium-derived factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 3. 
Cumulative retention rate of peritoneal dialysis (PD) patients. VEGF, vascular endothelial growth 
factor; Hb, hemoglobin. 
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